CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S.

Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations, and raised its full-year outlook, ...

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...

Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024. The decrease of $2.6 ...

Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy, ...

In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced ...

Nextcure ( ($NXTC) ) has released its Q3 earnings. Here is a breakdown of the information Nextcure presented to its investors. NextCure, Inc. is a ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or ...

The birds are an unlikely example of how public health fights have shifted political dynamics in ways the U.S. is influencing and reckoning with.